Lysosomal acid lipase deficiency - an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction
EAS Academy, Maurizio Averna, 175509
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Introduction
EAS Academy, Kausik Ray, 176674
Chronic kidney disease
EAS Academy, Alexandros Tselepis, 175502
Familial hypercholesterolaemia
EAS Academy, Kausik Ray, 175500
Primary prevention
EAS Academy, Guy de Backer, 175499
Secondary prevention
EAS Academy, Renata Cifkova, 175498
Prognostics in patients with manifest (acute or chronic) CHD
EAS Academy, Thomas Luscher, 175504
MODULE 5: GENETICS IN CARDIOVASCULAR DISEASE
EAS Academy, Course Faculty, 258491
Summary and introduction of guidelines
EAS Academy, Alberico L. Catapano, 175497
Using naturally randomized genetic evidence to understand heritability of coronary artery disease?
EAS Academy, Brian Ference, 175503
Lowering LDL-C for cardiovascular disease
EAS Academy, Chris Packard, 175496
The case for immune cells: An expanded cardiovascular continuum
EAS Academy, Peter Libby, 175495
Innate immune response drives atherosclerosis
EAS Academy, Mihai Netea, 175494
Role of non-coding RNA for cholesterol homeostasis and atherogenesis
EAS Academy, Kathryn Moore, 175493
Anitschkow Lecture: Hematopoiesis, cholesterol and atherosclerosis
EAS Academy, Alan Tall, 175492
Introduction to Anitschkow prize winner
EAS Academy, Lale Tokgozoglu, 176670
Progress in understanding the role of nutrition in prevention of atherosclerosis: Discussion
EAS Academy, Session Speakers, 176669
The new EAS/ESC Guidelines on diet and lifestyle in cardiovascular prevention
EAS Academy, Gabriele Riccardi, 175491
Nordic and Mediterranean diet patterns from the CVD point of view
EAS Academy, Ursula Schwab, 175490
Life time exposure to LDL-cholesterol is it the key to CVD risk?
EAS Academy, Brian Ference, 175489
Progress in understanding the role of nutrition in prevention of atherosclerosis: Chair
EAS Academy, Jan Borén, 176668
Closing remarks
EAS Academy, Alberico L. Catapano, 175488
Clinical Cases Discussion
EAS Academy, Session Speakers, 175487
PCSK9 Inhibition: HIGHLIGHTS FROM RECENT PUBLICATIONS
EAS Academy, Alberico L. Catapano, 175486
Combination Therapy with non-Statin lipid lowering therapies
EAS Academy, Stephen Nicholls, 175485
Lipid lowering therapies: statins
EAS Academy, Stephen Nicholls, 175484
HDL, non HDL cholesterol and TG: a role in atherosclerosis?
EAS Academy, Kausik Ray, 175483
Plasma lipoproteins and their role in atherogenesis
EAS Academy, Jan Borén, 175482
Familial hypercholesterolemia detection and treatment and the EAS Initiatives
EAS Academy, Kausik Ray, 175481
Panel discussion
EAS Academy, Session Speakers, 175549
Genetics for the identification of therapeutic targets in dyslipidaemia
EAS Academy, Brian Ference, 175480
CVD: Epidemiology of the risk factors: the central role of LDL cholesterol
EAS Academy, Lale Tokgozoglu, 175479
Lipid guidelines, where we stand?
EAS Academy, Alberico L. Catapano, 175478
PCSK9 inhibitor therapy - The cure for atherosclerosis?
EAS Academy, Frederick Raal, 175476
PCSK9: From promise to clinical practice
EAS Academy, Gilles Lambert, 175475
Epidemiology of dyslipidemias focus on the region
EAS Academy, Hung-I Yeh, 175474
Introduction to the course
EAS Academy, Alberico L. Catapano, 175473
Cases and questions to illustrate the EAS/ESC dyslipidaemia guidelines 2016
EAS Academy, Session Speakers, 166915
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The new lipid Guidelines
EAS Academy, Alberico L. Catapano, 164450
2016 ESC/EAS Guidelines on the Management of Dyslipidaemias: Part 1
EAS Academy, Lale Tokgozoglu, 164451
PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK FACTORS TO PREDICT CARDIOVASCULAR EVENTS
EAS Academy, Peter Meikle, 136740
CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT METABOLIC SYNDROME AND TYPE-2 DIABETES
EAS Academy, Peter Willeit, 136738
POPULATION APPROACH TO PREVENT CVD
EAS Academy, Eva Bossano Prescott, 136745
LIPIDS: WHAT IS NEW?
EAS Academy, Alberico L. Catapano, 136744
CIRCULATING CELLS AND CVD RISK
EAS Academy, Gerard Pasterkamp, 136737
WHAT ARE THE RISK FACTOR TARGETS?
EAS Academy, Ian Graham, 136743
HOW CAN WE IDENTIFY HIGH RISK?
EAS Academy, Ian Graham, 136742
INTRODUCTION: WHAT IS NEW IN THESE GUIDELINES?
EAS Academy, Olov Wiklund, 136741
LESSONS LEARNED FROM EMERGING THERAPIES FOR SEVERE HYPERTRIGLYCERIDEMIA
EAS Academy, Daniel Gaudet, 136735
THE USE OF NOVEL THERAPIES IN ATHEROSCLEROSIS: FROM ANTIBODIES TO NANOTECHNOLOGY
EAS Academy, Erik Stroes, 136734
IN INTEGRATIVE OMICS APPROACH IN HUMAN DISEASE RESEARCH
EAS Academy, Karsten Suhre, 136732
PLEIOTROPIC MOLECULAR TARGETS OF COXIBS REVEALS NOVEL GENOMIC LOCI CONFERRING CORONARY ARTERY DISEASE RISK
EAS Academy, Ingrid Braenne, 136726
WHAT DID WE LEARN FROM Lp(a)? SUMMARY OF THE SATELLITE MEETING
EAS Academy, Gert Kostner, 136731
DEEP SEQUENCING IDENTIFIES DNA METHYLATION DEPENDENT GENES IMPLICATED IN DIABETIC COMPLICATIONS
EAS Academy, Ishant Khurana, 136725
OBESITY AND INFLAMMATORY PROCESSES IN ADIPOSE TISSUE
EAS Academy, Giuseppe Danilo Norata, 136730
LEUKOCYTE TELOMERE LENGTH, GENETICALLY DETERMINED, IS CAUSALLY ASSOCIATED WITH THE PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS AND INCIDENCE OF CARDIOVASCULAR EVENTS
EAS Academy, Andrea Baragetti, 136724
CHANGE IN BODYMASS INDEX ASSOCIATED WITH LOWEST MORTALITY IN DENMARK
EAS Academy, Shoaib Afzal, 136729
GENETIC DISCOVERIES FOR LIPID GENETIC TRAITS. LESSON LEARNED FROM FAMILIES AND THE GENERAL POPULATION
EAS Academy, Samuli Ripatti, 136722
Low HDL High Triglyceride, Diabetic Dyslipidaemia: Conclusion & Discussion
EAS Academy, Session Speakers, 137121
Lysosomal Aci​d Lipase Deficiency: Conclusion & Discussion
EAS Academy, Session Speakers, 137180
Triglyceride, Remnants and Atherosclerosis
EAS Academy, Borge Nordestgaard, 136721
Lipid Metabolism Abnormalities in LAL-D as a lysosomal storage disease with a focus on specific signs and symptoms
EAS Academy, Maurizio Averna, 137179
Diabetic Dyslipidaemia
EAS Academy, Alberto Zambon, 136720
Lysosomal Aci​d Lipase Deficiency: Chair
EAS Academy, Petri Kovanen, 137177
Lipid Metabolism Abnormalities in general with differential diagnoses including also LAL-D
EAS Academy, Thomas Stulning, 137178
Low HDL High Triglyceride, Diabetic Dyslipidaemia: Chair
EAS Academy, Olov Wiklund, 137181
NAFLD - THE NOVEL TREAT FOR VASCULAR DISEASE
EAS Academy, Marja-Riitta Taskinen, 136719
TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE
EAS Academy, Vasanti Malik, 136718
DOES THE HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST?
EAS Academy, Luc Van Gaal, 136717
MANAGEMENT OF SUBJECTS AT HIGH CARDIOMETABOLIC RISK - WHERE DO WE FALL?
EAS Academy, Jean-Pierre Despres, 136716
ADIPOSE TISSUE BROWNING AND METABOLIC HEALTH
EAS Academy, Joerg Heeren, 136713
HOW GENES CONTROL CHOLESTEROL
EAS Academy, Michael S. Brown, 136711
SEX-SPECIFIC GENOMIC AND PROTEOMIC REGULATION IN CARDIOVASCULAR DISEASE
EAS Academy, Georgios Kararigas, 136710
SEX-SPECIFIC BIOMARKERS FOR CARDIOVASCULAR DISEASES
EAS Academy, Borge Nordestgaard, 136709
SEX DIFFERENCES IN HEART DISEASE IN CLINICAL PRACTICE
EAS Academy, Eva Bossano Prescott, 136708
PUBLIC HEALTH PERSPECTIVES ON CARDIOVASCULAR CARE FOR MEN AND WOMEN
EAS Academy, Kornelia Kotseva, 136707
Discussion and Conclusion​
EAS Academy, Session Speakers, 137187
Plant Nutraceuticals for the treatment of hypercholesterolemia: The available clinical data
EAS Academy, Eric Bruckert, 137186
To bridge the gap between lifestyle and Pharmacological treatment: do we have an unmet need?
EAS Academy, bernhard paulweber, 137185
Nutraceuticals with​ lipid lowering activity​: who can benefit?​: Chairman’s welcome
EAS Academy, Gerd Assmann, 137182
Role of Nutrition in Disease Pathology: Discussion
EAS Academy, Session Speakers, 137120
NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS AND FATTY LIVER DISEASE
EAS Academy, Jaime Mas-Oliva, 136706
SATURATED FAT IN THE DIET: GOOD OR BAD?
EAS Academy, Ingeborg Brouwer, 136701
CURRENT STATUS-PHASE I TRIAL OF CELL-TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS IN SEVERE FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS UNDERGOING LDL-APHERESIS
EAS Academy, Masahiro Koseki, 136705
A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAT FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
EAS Academy, Alastair Kerr, 136704
ROLE OF SODIUM IN ATHEROSCLEROSIS
EAS Academy, Jens M. Titze, 136700
Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians?: Discussion
EAS Academy, Session Speakers, 137119
COMPARATIVE EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION, STATIN AND EZETIMIBE THERAPY ON ATHEROGENIC AND PROTECTIVE LIPID FACTORS: THE ACCENTUATE TRIAL
EAS Academy, Stephen Nicholls, 136703
LESSONS FROM CLINICAL TRIALS
EAS Academy, Jane Armitage, 136699
LESSONS FROM CLINICAL EXPERIENCE
EAS Academy, Urlich Laufs, 136698
ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING
EAS Academy, Francois Mach, 136702
Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? Chair
EAS Academy, Chris Packard, 137123
LEADING THE WAY TO GENETICS AND PHARMACOGENOMICS IN THE CLINIC
EAS Academy, Teri Manolio, 136696
GWAS FOR CORONARY ARTERY DISEASE
EAS Academy, Heribert Schunkert, 136695
GENETIC PROTECTION FROM CORONARY ARTERY DISEASE: THE ROLE OF ABCG5 AND ABCG8
EAS Academy, Helen Hobbs, 136694
PANEL DISCUSSION
EAS Academy, Session Speakers, 137188
ROLE OF MICROBIOTA ON CARDIOVASCULAR DISEASE
EAS Academy, Jingyuan Fu, 136680
PLANT STEROL AND STANOLS AND CARDIOVASCULAR DISEASE. IMPACT OF ENRICHED FOODS AND CHOLESTEROL LOWERING DRUGS
EAS Academy, John Chapman, 136679

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings